BioMarin Pharmaceutical (BMRN) EBITDA Margin: History & Chart

BioMarin Pharmaceutical Inc.(BMRN)

Biotechnology · San Rafael, CA

$57.54+0.36 (+0.63%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.

San Rafael, CA

3,221 employees

www.biomarin.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Alexander Hardy

View full financials

BMRN EBITDA Margin Metrics

EBITDA MARGIN

19.03%

EBITDA MARGIN AVG TTM

16.74%

EBITDA MARGIN AVG 3Y

17.90%

EBITDA MARGIN AVG 5Y

13.55%

EBITDA MARGIN AVG 10Y

7.13%

EBITDA MARGIN AVG 15Y

0.40%

EBITDA MARGIN AVG 20Y

1.67%

CURRENT VS TTM AVG

+13.67%

CURRENT VS 3Y AVG

+6.30%

CURRENT VS 5Y AVG

+40.40%

CURRENT VS 10Y AVG

+166.81%

CURRENT VS 15Y AVG

+4692.16%

CURRENT VS 20Y AVG

+1039.42%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
BioMarin Pharmaceutical Inc. (BMRN)	$11.12B	19.03%	16.74%	17.90%	13.55%
The Cooper Companies, Inc. (COO)vs ›	$11.07B	27.02%	27.38%	26.41%	26.36%
Bio-Techne Corporation (TECH)vs ›	$11.36B	28.74%	23.07%	27.33%	30.04%
ImmunityBio, Inc. (IBRX)vs ›	$10.87B	-212.29%	-1213.73%	-49114.16%	-44116.26%
DaVita Inc. (DVA)vs ›	$11.47B	19.98%	20.97%	19.78%	20.10%
Universal Health Services, Inc. (UHS)vs ›	$10.66B	15.05%	14.69%	13.35%	14.10%
Globus Medical, Inc. (GMED)vs ›	$10.33B	20.41%	18.54%	20.94%	21.85%
Encompass Health Corporation (EHC)vs ›	$12.00B	23.27%	22.46%	26.66%	22.37%
Bio-Rad Laboratories, Inc. (BIO)vs ›	$10.22B	18.42%	17.41%	19.12%	20.05%
Molina Healthcare, Inc. (MOH)vs ›	$10.13B	2.15%	3.41%	4.20%	4.49%

NAME

MARKET CAP

EBITDA MARGIN

TTM

BioMarin Pharmaceutical Inc. (BMRN)

$11.12B

19.03%

16.74%

17.90%

13.55%

The Cooper Companies, Inc. (COO)vs ›

$11.07B

27.02%

27.38%

26.41%

26.36%

Bio-Techne Corporation (TECH)vs ›

$11.36B

28.74%

23.07%

27.33%

30.04%

ImmunityBio, Inc. (IBRX)vs ›

$10.87B

-212.29%

-1213.73%

-49114.16%

-44116.26%

DaVita Inc. (DVA)vs ›

$11.47B

19.98%

20.97%

19.78%

20.10%

Universal Health Services, Inc. (UHS)vs ›

$10.66B

15.05%

14.69%

13.35%

14.10%

Globus Medical, Inc. (GMED)vs ›

$10.33B

20.41%

18.54%

20.94%

21.85%

Encompass Health Corporation (EHC)vs ›

$12.00B

23.27%

22.46%

26.66%

22.37%

Bio-Rad Laboratories, Inc. (BIO)vs ›

$10.22B

18.42%

17.41%

19.12%

20.05%

Molina Healthcare, Inc. (MOH)vs ›

$10.13B

2.15%

3.41%

4.20%

4.49%

EBITDA Margin FAQ

What is the EBITDA margin for BioMarin Pharmaceutical Inc. (BMRN)?

The EBITDA margin for BMRN stock is 19.03%.

Is BioMarin Pharmaceutical Inc.'s EBITDA margin high or low?

The EBITDA margin of 19.03% is 40% above its 5-year average of 13.55%, around the middle of its 5-year range (-8.87%–35.79%).

What is the TTM average EBITDA margin for BioMarin Pharmaceutical Inc. (BMRN)?

The TTM average EBITDA margin for BMRN stock is 16.74%.

What is the 3Y average EBITDA margin for BioMarin Pharmaceutical Inc. (BMRN)?

The 3Y average EBITDA margin for BMRN stock is 17.90%.

What is the 5Y average EBITDA margin for BioMarin Pharmaceutical Inc. (BMRN)?

The 5Y average EBITDA margin for BMRN stock is 13.55%.

What is the 10Y average EBITDA margin for BioMarin Pharmaceutical Inc. (BMRN)?

The 10Y average EBITDA margin for BMRN stock is 7.13%.

What is the 15Y average EBITDA margin for BioMarin Pharmaceutical Inc. (BMRN)?

The 15Y average EBITDA margin for BMRN stock is 0.40%.

What is the 20Y average EBITDA margin for BioMarin Pharmaceutical Inc. (BMRN)?

The 20Y average EBITDA margin for BMRN stock is 1.67%.

DATE	EBITDA MARGIN
2026-06-30	21.07%
2026-03-31	19.06%
2025-12-31	11.41%
2025-09-30	-3.63%
2025-06-30	35.79%
2025-03-31	33.01%
2024-12-31	24.76%
2024-09-30	17.82%
2024-06-30	20.63%
2024-03-31	17.85%
2023-12-31	6.36%
2023-09-30	9.67%
2023-06-30	15.28%
2023-03-31	14.89%
2022-12-31	0.01%
2022-09-30	4.43%
2022-06-30	12.07%
2022-03-31	31.71%
2021-12-31	-8.87%
2021-09-30	-6.45%
2021-06-30	7.75%
2021-03-31	10.92%
2020-12-31	-3.87%
2020-09-30	-6.15%
2020-06-30	-3.66%
2020-03-31	26.08%
2019-12-31	3.66%
2019-09-30	7.54%
2019-06-30	-3.87%
2019-03-31	-7.87%
2018-12-31	-3.80%
2018-09-30	2.71%
2018-06-30	-1.15%
2018-03-31	-5.55%
2017-12-31	24.20%
2017-09-30	2.09%
2017-06-30	-6.21%
2017-03-31	-0.26%
2016-12-31	-23.16%
2016-09-30	-10.96%
2016-06-30	-181.30%
2016-03-31	-26.27%
2015-12-31	45.28%
2015-09-30	-33.43%
2015-06-30	-21.13%
2015-03-31	-27.13%
2014-12-31	-18.16%
2014-09-30	14.40%
2014-06-30	-2.71%
2014-03-31	-9.54%
2013-12-31	-29.23%
2013-09-30	-27.33%
2013-06-30	-5.25%
2013-03-31	-16.86%
2012-12-31	-26.56%
2012-09-30	0.92%
2012-06-30	-15.95%
2012-03-31	-9.66%
2011-12-31	-10.95%
2011-09-30	-5.44%
2011-06-30	8.41%
2011-03-31	9.94%
2010-12-31	4.51%
2010-09-30	6.02%
2010-06-30	10.46%
2010-03-31	9.65%
2009-12-31	12.91%
2009-09-30	18.53%
2009-06-30	12.66%
2009-03-31	0.95%
2008-12-31	42.59%
2008-09-30	15.40%
2008-06-30	11.74%
2008-03-31	3.06%
2007-12-31	-20.31%
2007-06-30	-46.62%
2007-03-31	-69.82%
2006-12-31	-40.88%
2006-09-30	-4.13%
2006-06-30	10.40%
2006-03-31	-37.09%
2005-12-31	-106.08%
2005-09-30	-141.77%
2005-06-30	-451.43%
2005-03-31	-340.23%
2004-12-31	-568.22%
2004-09-30	-13517.13%
2004-06-30	-1110.45%
2003-06-30	-61.46%
2003-03-31	-527.97%
2002-12-31	-777.26%
2002-09-30	-354.86%

DATE

EBITDA MARGIN

2026-06-30

21.07%

2026-03-31

19.06%

2025-12-31

11.41%

2025-09-30

-3.63%

2025-06-30

35.79%

2025-03-31

33.01%

2024-12-31

24.76%

2024-09-30

17.82%

2024-06-30

20.63%

2024-03-31

17.85%

2023-12-31

6.36%

2023-09-30

9.67%

2023-06-30

15.28%

2023-03-31

14.89%

2022-12-31

0.01%

2022-09-30

4.43%

2022-06-30

12.07%

2022-03-31

31.71%

2021-12-31

-8.87%

2021-09-30

-6.45%

2021-06-30

7.75%

2021-03-31

10.92%

2020-12-31

-3.87%

2020-09-30

-6.15%

2020-06-30

-3.66%

2020-03-31

26.08%

2019-12-31

3.66%

2019-09-30

7.54%

2019-06-30

-3.87%

2019-03-31

-7.87%

2018-12-31

-3.80%

2018-09-30

2.71%

2018-06-30

-1.15%

2018-03-31

-5.55%

2017-12-31

24.20%

2017-09-30

2.09%

2017-06-30

-6.21%

2017-03-31

-0.26%

2016-12-31

-23.16%

2016-09-30

-10.96%

2016-06-30

-181.30%

2016-03-31

-26.27%

2015-12-31

45.28%

2015-09-30

-33.43%

2015-06-30

-21.13%

2015-03-31

-27.13%

2014-12-31

-18.16%

2014-09-30

14.40%

2014-06-30

-2.71%

2014-03-31

-9.54%

2013-12-31

-29.23%

2013-09-30

-27.33%

2013-06-30

-5.25%

2013-03-31

-16.86%

2012-12-31

-26.56%

2012-09-30

0.92%

2012-06-30

-15.95%

2012-03-31

-9.66%

2011-12-31

-10.95%

2011-09-30

-5.44%

2011-06-30

8.41%

2011-03-31

9.94%

2010-12-31

4.51%

2010-09-30

6.02%

2010-06-30

10.46%

2010-03-31

9.65%

2009-12-31

12.91%

2009-09-30

18.53%

2009-06-30

12.66%

2009-03-31

0.95%

2008-12-31

42.59%

2008-09-30

15.40%

2008-06-30

11.74%

2008-03-31

3.06%

2007-12-31

-20.31%

2007-06-30

-46.62%

2007-03-31

-69.82%

2006-12-31

-40.88%

2006-09-30

-4.13%

2006-06-30

10.40%

2006-03-31

-37.09%

2005-12-31

-106.08%

2005-09-30

-141.77%

2005-06-30

-451.43%

2005-03-31

-340.23%

2004-12-31

-568.22%

2004-09-30

-13517.13%

2004-06-30

-1110.45%

2003-06-30

-61.46%

2003-03-31

-527.97%

2002-12-31

-777.26%

2002-09-30

-354.86%

EBITDA Margin: 19.03%

BMRN EBITDA Margin

BMRN Average EBITDA Margin Chart

BMRN Current vs Average EBITDA Margin Chart

BMRN EBITDA Margin Metrics

BMRN Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

BMRN EBITDA Margin History

Related Metrics